Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: ROCK2

Gene summary for ROCK2

Gene summary.

Gene information	Species	Human
	Gene symbol	ROCK2
	Gene ID	9475
	Gene name	Rho associated coiled-coil containing protein kinase 2
	Gene Alias	ROCK-II
	Cytomap	2p25.1
	Gene Type	protein-coding
	GO ID	GO:0000165
	UniProtAcc	O75116

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
9475	ROCK2	CCI_2	Human	Cervix	CC	8.74e-08	8.19e-01	0.5249
9475	ROCK2	CCI_3	Human	Cervix	CC	2.99e-03	6.37e-01	0.516
9475	ROCK2	HTA11_3410_2000001011	Human	Colorectum	AD	3.53e-02	-2.80e-01	0.0155
9475	ROCK2	HTA11_1938_2000001011	Human	Colorectum	AD	1.56e-05	6.22e-01	-0.0811
9475	ROCK2	HTA11_347_2000001011	Human	Colorectum	AD	1.96e-09	5.90e-01	-0.1954
9475	ROCK2	HTA11_411_2000001011	Human	Colorectum	SER	1.02e-06	7.49e-01	-0.2602
9475	ROCK2	HTA11_1391_2000001011	Human	Colorectum	AD	8.84e-03	5.18e-01	-0.059
9475	ROCK2	HTA11_866_3004761011	Human	Colorectum	AD	2.59e-02	-3.79e-01	0.096
9475	ROCK2	HTA11_8622_2000001021	Human	Colorectum	SER	4.22e-05	-4.02e-01	0.0528
9475	ROCK2	HTA11_99999965104_69814	Human	Colorectum	MSS	1.07e-04	6.04e-01	0.281
9475	ROCK2	HTA11_99999971662_82457	Human	Colorectum	MSS	9.58e-05	5.75e-01	0.3859
9475	ROCK2	HTA11_99999974143_84620	Human	Colorectum	MSS	6.62e-07	5.58e-01	0.3005
9475	ROCK2	F007	Human	Colorectum	FAP	5.84e-03	1.44e-01	0.1176
9475	ROCK2	A002-C-010	Human	Colorectum	FAP	1.18e-04	1.78e-01	0.242
9475	ROCK2	A001-C-207	Human	Colorectum	FAP	2.09e-05	1.05e-01	0.1278
9475	ROCK2	A015-C-203	Human	Colorectum	FAP	6.50e-30	-1.60e-01	-0.1294
9475	ROCK2	A015-C-204	Human	Colorectum	FAP	1.22e-06	-1.56e-01	-0.0228
9475	ROCK2	A014-C-040	Human	Colorectum	FAP	2.49e-06	-2.39e-01	-0.1184
9475	ROCK2	A002-C-201	Human	Colorectum	FAP	1.25e-15	-3.72e-02	0.0324
9475	ROCK2	A002-C-203	Human	Colorectum	FAP	4.43e-03	1.10e-01	0.2786

Page: 1 2 3 4 5 6 7 8 9 10

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Cervix		CC: Cervix cancer
		HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions
		N_HPV: HPV-infected normal cervix
Colorectum (GSE201348)		FAP: Familial adenomatous polyposis
		CRC: Colorectal cancer
Colorectum (HTA11)		AD: Adenomas
		SER: Sessile serrated lesions
		MSI-H: Microsatellite-high colorectal cancer
		MSS: Microsatellite stable colorectal cancer
Endometrium		AEH: Atypical endometrial hyperplasia
		EEC: Endometrioid Cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Lung		AAH: Atypical adenomatous hyperplasia
		AIS: Adenocarcinoma in situ
		IAC: Invasive lung adenocarcinoma
		MIA: Minimally invasive adenocarcinoma
Prostate		BPH: Benign Prostatic Hyperplasia
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:001603210	Cervix	CC	viral process	109/2311	415/18723	5.40e-15	6.46e-12	109
GO:001081010	Cervix	CC	regulation of cell-substrate adhesion	69/2311	221/18723	8.57e-14	5.69e-11	69
GO:00315898	Cervix	CC	cell-substrate adhesion	96/2311	363/18723	1.48e-13	8.85e-11	96
GO:001905810	Cervix	CC	viral life cycle	87/2311	317/18723	2.20e-13	1.20e-10	87
GO:000701510	Cervix	CC	actin filament organization	109/2311	442/18723	4.92e-13	2.45e-10	109
GO:005254710	Cervix	CC	regulation of peptidase activity	112/2311	461/18723	6.70e-13	3.08e-10	112
GO:004586210	Cervix	CC	positive regulation of proteolysis	95/2311	372/18723	1.84e-12	6.86e-10	95
GO:005254810	Cervix	CC	regulation of endopeptidase activity	103/2311	432/18723	1.89e-11	5.14e-09	103
GO:009013210	Cervix	CC	epithelium migration	90/2311	360/18723	2.45e-11	6.11e-09	90
GO:00016679	Cervix	CC	ameboidal-type cell migration	110/2311	475/18723	2.66e-11	6.36e-09	110
GO:001063110	Cervix	CC	epithelial cell migration	89/2311	357/18723	3.72e-11	8.54e-09	89
GO:00085446	Cervix	CC	epidermis development	83/2311	324/18723	3.91e-11	8.54e-09	83
GO:003297010	Cervix	CC	regulation of actin filament-based process	96/2311	397/18723	4.00e-11	8.54e-09	96
GO:00071639	Cervix	CC	establishment or maintenance of cell polarity	63/2311	218/18723	4.25e-11	8.76e-09	63
GO:009013010	Cervix	CC	tissue migration	90/2311	365/18723	5.42e-11	1.05e-08	90
GO:00435884	Cervix	CC	skin development	71/2311	263/18723	8.04e-11	1.46e-08	71
GO:190290310	Cervix	CC	regulation of supramolecular fiber organization	92/2311	383/18723	1.49e-10	2.48e-08	92
GO:190382910	Cervix	CC	positive regulation of cellular protein localization	72/2311	276/18723	3.20e-10	4.46e-08	72
GO:01501159	Cervix	CC	cell-substrate junction organization	37/2311	101/18723	3.20e-10	4.46e-08	37
GO:007265910	Cervix	CC	protein localization to plasma membrane	73/2311	284/18723	4.95e-10	6.73e-08	73

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136

Enriched KEGG pathways.

Pathway ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	qvalue	Count
hsa0513020	Cervix	CC	Pathogenic Escherichia coli infection	63/1267	197/8465	9.28e-10	2.00e-08	1.19e-08	63
hsa0541720	Cervix	CC	Lipid and atherosclerosis	65/1267	215/8465	6.47e-09	1.10e-07	6.52e-08	65
hsa0516318	Cervix	CC	Human cytomegalovirus infection	65/1267	225/8465	4.59e-08	6.47e-07	3.83e-07	65
hsa0513120	Cervix	CC	Shigellosis	69/1267	247/8465	7.64e-08	1.03e-06	6.10e-07	69
hsa0520516	Cervix	CC	Proteoglycans in cancer	60/1267	205/8465	9.13e-08	1.18e-06	7.00e-07	60
hsa0451010	Cervix	CC	Focal adhesion	59/1267	203/8465	1.53e-07	1.84e-06	1.09e-06	59
hsa0481016	Cervix	CC	Regulation of actin cytoskeleton	64/1267	229/8465	2.24e-07	2.59e-06	1.53e-06	64
hsa0452020	Cervix	CC	Adherens junction	33/1267	93/8465	6.99e-07	7.31e-06	4.32e-06	33
hsa0453020	Cervix	CC	Tight junction	49/1267	169/8465	1.87e-06	1.78e-05	1.05e-05	49
hsa0467020	Cervix	CC	Leukocyte transendothelial migration	36/1267	114/8465	5.22e-06	4.83e-05	2.86e-05	36
hsa0513516	Cervix	CC	Yersinia infection	39/1267	137/8465	3.27e-05	2.41e-04	1.42e-04	39
hsa0407110	Cervix	CC	Sphingolipid signaling pathway	35/1267	121/8465	5.70e-05	3.93e-04	2.32e-04	35
hsa043609	Cervix	CC	Axon guidance	47/1267	182/8465	8.13e-05	5.38e-04	3.18e-04	47
hsa043109	Cervix	CC	Wnt signaling pathway	43/1267	171/8465	3.03e-04	1.64e-03	9.68e-04	43
hsa04062	Cervix	CC	Chemokine signaling pathway	43/1267	192/8465	3.60e-03	1.34e-02	7.91e-03	43
hsa049218	Cervix	CC	Oxytocin signaling pathway	34/1267	154/8465	1.12e-02	3.42e-02	2.02e-02	34
hsa046115	Cervix	CC	Platelet activation	28/1267	124/8465	1.50e-02	4.45e-02	2.63e-02	28
hsa05130110	Cervix	CC	Pathogenic Escherichia coli infection	63/1267	197/8465	9.28e-10	2.00e-08	1.19e-08	63
hsa05417110	Cervix	CC	Lipid and atherosclerosis	65/1267	215/8465	6.47e-09	1.10e-07	6.52e-08	65
hsa0516319	Cervix	CC	Human cytomegalovirus infection	65/1267	225/8465	4.59e-08	6.47e-07	3.83e-07	65

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

ROCK2

SNV

Missense_Mutation

novel

c.3226N>C

p.Lys1076Gln

p.K1076Q

O75116

protein_coding

deleterious(0)

probably_damaging(0.946)

TCGA-AN-A046-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

ROCK2

SNV

Missense_Mutation

rs747260728

c.1715N>A

p.Arg572Gln

p.R572Q

O75116

protein_coding

tolerated(0.38)

benign(0.065)

TCGA-AN-A046-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

ROCK2

SNV

Missense_Mutation

c.3560N>A

p.Ser1187Asn

p.S1187N

O75116

protein_coding

tolerated(0.16)

benign(0.097)

TCGA-AN-A0FL-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

ROCK2

SNV

Missense_Mutation

c.4091G>C

p.Arg1364Thr

p.R1364T

O75116

protein_coding

deleterious(0.01)

benign(0.041)

TCGA-AR-A0TX-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

ROCK2

SNV

Missense_Mutation

c.1849N>C

p.Glu617Gln

p.E617Q

O75116

protein_coding

tolerated(0.34)

benign(0.083)

TCGA-BH-A0HP-01

Breast

breast invasive carcinoma

Female

>=65

III/IV

Chemotherapy

doxorubicin

ROCK2

SNV

Missense_Mutation

novel

c.2329N>C

p.Glu777Gln

p.E777Q

O75116

protein_coding

tolerated(0.67)

benign(0.028)

TCGA-PE-A5DE-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

taxotere

ROCK2

SNV

Missense_Mutation

novel

c.186N>C

p.Leu62Phe

p.L62F

O75116

protein_coding

deleterious(0.02)

probably_damaging(0.95)

TCGA-XX-A89A-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

ROCK2

insertion

Nonsense_Mutation

novel

c.2665_2666insCAATTTAACTATAATCCAA

p.Glu889AlafsTer3

p.E889Afs*3

O75116

protein_coding

TCGA-AR-A0U0-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

ROCK2

SNV

Missense_Mutation

novel

c.712A>C

p.Lys238Gln

p.K238Q

O75116

protein_coding

deleterious(0)

probably_damaging(0.929)

TCGA-2W-A8YY-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

ROCK2

SNV

Missense_Mutation

c.2719N>A

p.Glu907Lys

p.E907K

O75116

protein_coding

deleterious(0)

probably_damaging(0.957)

TCGA-DR-A0ZM-01

Cervix

cervical & endocervical cancer

Female

<65

III/IV

Unspecific

Cisplatin

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID	Symbol	Category	Interaction Types	Drug Claim Name	Drug Name	PMIDs
9475	ROCK2	KINASE, ENZYME, DRUGGABLE GENOME, SERINE THREONINE KINASE	inhibitor	178102655
9475	ROCK2	KINASE, ENZYME, DRUGGABLE GENOME, SERINE THREONINE KINASE		AR-12286	VEROSUDIL
9475	ROCK2	KINASE, ENZYME, DRUGGABLE GENOME, SERINE THREONINE KINASE		BAY-613606	CHEMBL541400
9475	ROCK2	KINASE, ENZYME, DRUGGABLE GENOME, SERINE THREONINE KINASE		AST-487	AST-487
9475	ROCK2	KINASE, ENZYME, DRUGGABLE GENOME, SERINE THREONINE KINASE		THROMBIN	THROMBIN	16720831
9475	ROCK2	KINASE, ENZYME, DRUGGABLE GENOME, SERINE THREONINE KINASE	inhibitor	178101973
9475	ROCK2	KINASE, ENZYME, DRUGGABLE GENOME, SERINE THREONINE KINASE		KD025
9475	ROCK2	KINASE, ENZYME, DRUGGABLE GENOME, SERINE THREONINE KINASE		VER-49009	CHEMBL365617
9475	ROCK2	KINASE, ENZYME, DRUGGABLE GENOME, SERINE THREONINE KINASE		Tricyclic compound 4
9475	ROCK2	KINASE, ENZYME, DRUGGABLE GENOME, SERINE THREONINE KINASE	inhibitor	310264692	VEROSUDIL

Page: 1 2 3 4 5 6 7 8